Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372628 · ClinicalTrials.gov registry record · Phase 2
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
A Phase 2 study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 452
- Enrollment target
NCT04372628 is a Phase 2 study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 452 participants.
The verdict
NCT04372628, a Phase 2 study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 452 participants
- Enrollment target
Study Summary
Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19
Interventions
- OTHER Placebo
- DRUG Lopinavir/Ritonavir 400 mg/100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2020-06-01 |
| Est. Completion | 2022-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04372628
The ClinicalTrials.gov registry entry for NCT04372628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 452 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04372628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04372628 about?
NCT04372628 is a clinical study titled "Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19". Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19
What is the current status of trial NCT04372628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 452 participants. The study started on 2020-06-01. Estimated completion is 2022-01-18.
What interventions are being tested in trial NCT04372628?
The interventions under investigation include: Placebo (OTHER), Lopinavir/Ritonavir 400 mg/100 mg (DRUG).
Who is sponsoring clinical trial NCT04372628?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.